Research programme: natural killer T cell-based therapeutics - NKT Therapeutics

Drug Profile

Research programme: natural killer T cell-based therapeutics - NKT Therapeutics

Alternative Names: iNKT mAb; NKTT 320

Latest Information Update: 20 Feb 2013

Price : $50

At a glance

  • Originator NKT-Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Natural killer cell modulators; Natural killer cell receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Asthma; Atopic dermatitis; Autoimmune disorders; Cancer; Sickle cell anaemia

Most Recent Events

  • 20 Feb 2013 Preclinical development is ongoing in USA (\\);
  • 07 Dec 2012 Preclinical trials in Sickle cell anaemia in USA (Parenteral)
  • 08 Feb 2011 NKT signs contract with DSM for lead product process development and manufacture
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top